Safety and Efficacy of Combination Therapy (Danazol + Prednisolone + Thalidomide) in Thalidomide-Refractory Transfusion-Dependent β-Thalassemia Patients: A Prospective Randomized Controlled Clinical Trial
This study will compare two treatments for children with beta-thalassemia who need regular blood transfusions and have not responded well to thalidomide. One group will continue thalidomide alone. The other group will receive thalidomide plus danazol and prednisolone. The study will check whether the combination treatment reduces the need for blood transfusions, raises hemoglobin levels, and is safe. About 172 children aged 5 to 15 will be assigned by chance to one of the two groups. They will be followed for 9 to 12 months.
• Age 5 to 15 years with confirmed transfusion-dependent beta-thalassemia major.
• Documented non-response to adequately dosed thalidomide therapy for at least 6 months.
• Pre-transfusion hemoglobin less than 9.0 g/dL with continued transfusion dependence (more than 2 units per month).
• Adequate baseline clinical and laboratory assessment for safe study treatment.
• Stable transfusion and iron-chelation regimen according to the protocol.
• Written informed consent from parent/legal guardian and age-appropriate assent from the participant, with willingness to comply with study procedures and follow-up.